The aim of this pilot study was to determine the baseline state of oxidative stress indices in patients with Parkinson's disease (PD). Peripheral blood samples of 15 PD subjects were analyzed and compared with ten age matched healthy controls. Patients with PARK2 mutations were also compared with PD patients without mutations. There was significant increase in malondialdehyde content and superoxide-dismutase (SOD) activity in peripheral blood parameters in PD patients (p < 0.05) in comparison to controls. These findings suggest an important role of oxidative stress in Parkinson's disease evolution and progress. No changes were observed in glutathione peroxidase and nitric oxide levels. We found significant correlation between SOD activity and lipid peroxidation when the biochemical data was further analyzed. In addition, significant increase in the levels of SOD among the PD patients with PARK2 mutations was observed, which can be ascribed to chronic oxidative stress induced by PARK2 mutations.
The novel MAO-B inhibitor PF9601N, its cytochrome P450-dependent metabolite FA72 and l-deprenyl were studied as potential peroxynitrite (ONOO-) scavengers and nitric oxide synthase (NOS) inhibitors. The scavenging activity of these compounds was evaluated by measuring the oxygen consumption through peroxynitrite-mediated oxidation of both linoleic acid and brain homogenate. FA72, PF9601N and l-deprenyl caused a concentration-dependent inhibition of ONOO--induced linoleic acid oxidation with an IC50 value of 60.2 µM, 82.8 µM and 235.8 µM, respectively. FA72 was the most potent also in inhibiting ONOO--induced brain homogenate oxidation with an IC50 value of 99.4 µM, while PF9601N and l-deprenyl resulted weaker inhibitors in the same experimental model, showing an IC50 value of 164.8 and 112.0 µM, respectively. Furthermore, both the novel MAO-B inhibitor as well as its metabolite were able to strongly inhibit rat brain neuronal NOS (IC50 of 183 µM and 192 µM, respectively), while l-deprenyl at the highest concentration used (3 mM), caused only a slight decrease of the enzyme activity. Moreover, inducible NOS was strongly inhibited by FA72 only. All these results suggest that PF9601N could be a promising therapeutic agent in neurodegenerative disorders such as Parkinson's disease.
Celem pracy była ocena niektórych parametrów chodu osób z chorobą Parkinsona przy przechodzeniu odcinków prostych określonej trasy i slalomu. Badaniem objęto dwie grupy: grupę badawczą złożongą z 17 chorych na chorobę Parkinsona (średnia wieku 71 lat) i 17-osobową grupę kontrolną reprezentowaną przez osoby zdrowe (średnia wieku 70 lat). Badanie polegało na przejściu trasy, uwzględniającej odcinki proste i slalomu, wytyczonej wg pomysłu autorów pracy. Osoby z chorobą Parkinsona osiągały gorsze parametry chodu w stosunku do osób zdrowych w analogicznym przedziale wiekowym, zwłaszcza na odcinkach slalomu.
EN
The aim of the paper was to evaluate chosen gait parameters in patients with the Parkinson's disease while walking on straight sections and slalom of a chosen route. The research covered two groups: the examination group numbering 17 patients with the Parkinson's disease (average age 71 years) and the control group including 17 healthy people (average age 70 years). The examination was based on covering a route consisting of straight sections and slaloms, designed according to the idea of the authors. Patients with the Parkinson's disease achieved worse results in comparison with healthy people of similar age, especially on the slalom distances.
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.